-
-
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).
-
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.
-
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone.
-
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.
-
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population.
-
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work.
-
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data.
-
Calculating 60-day mortality risk by these readily available parameters (ECOG PS and WBC) can be used to identify high-risk patients who may require heightened surveillance after standard or experimental chemotherapy or, alternatively, a reduction in treatment intensity.
-
Hopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria.
